Evidence map›Paper›PMID 21483824›Full record

ArticlePloS one2011

1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor.

Ferdinand Molnár, Rita Sigüeiro, Yoshiteru Sato, Clarisse Araujo, Inge Schuster, Pierre Antony, Jean Peluso, Christian Muller, Antonio Mouriño, Dino Moras and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 85 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. A Non-Invasive Hair Test to Determine Vitamin DMolecules (Basel, Switzerland) · 2021
    Article
  10. Review
  11. Article
  12. Epimers of Vitamin D: A Review.International journal of molecular sciences · 2020
    Review
  13. Association of Differing Qatari Genotypes with Vitamin D Metabolites.International journal of endocrinology · 2020
    Article
  14. Association of vitamin DTherapeutic advances in chronic disease · 2020
    Article
  15. Vitamin D Metabolism Revised: Fall of Dogmas.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Review
  16. Vitamin D and Its Synthetic Analogs.Journal of medicinal chemistry · 2019
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Ferdinand MolnárInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), U964/Centre National de Recherche Scientifique (CNRS) UMR 7104/Université de Strasbourg, Illkirch, France.
Rita Sigüeiro
Yoshiteru Sato
Clarisse Araujo
Inge Schuster
Pierre Antony
Jean Peluso
Christian Muller
Antonio Mouriño
Dino Moras
Natacha Rochel
Centre National de la Recherche Scientifique · FRUniversidade de Santiago de Compostela · ESInstitut de génétique et de biologie moléculaire et cellulaire · FRInserm · FRUniversité de Strasbourg · FRUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe 1α,25-dihydroxy-3-epi-vitamin-D3 (1α,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator. In vivo action of 1α,25(OH)2-3-epi-D3 is tissue-specific and exhibits lowest calcemic effect compared to that induced by 1α,25(OH)2D3. To further unveil the structural mechanism and structure-activity relationships of 1α,25(OH)2-3-epi-D3 and its receptor complex, we characterized some of its in vitro biological properties and solved its crystal structure complexed with human VDR ligand-binding domain (LBD). METHODOLOGY/PRINCIPAL

findingsIn the present study, we report the more effective synthesis with fewer steps that provides higher yield of the 3-epimer of the 1α,25(OH)2D3. We solved the crystal structure of its complex with the human VDR-LBD and found that this natural metabolite displays specific adaptation of the ligand-binding pocket, as the 3-epimer maintains the number of hydrogen bonds by an alternative water-mediated interaction to compensate the abolished interaction with Ser278. In addition, the biological activity of the 1α,25(OH)2-3-epi-D3 in primary human keratinocytes and biochemical properties are comparable to 1α,25(OH)2D3. CONCLUSIONS/SIGNIFICANCE: The physiological role of this pathway as the specific biological action of the 3-epimer remains unclear. However, its high metabolic stability together with its significant biologic activity makes this natural metabolite an interesting ligand for clinical applications. Our new findings contribute to a better understanding at molecular level how natural metabolites of 1α,25(OH)2D3 lead to significant activity in biological systems and we conclude that the C3-epimerization pathway produces an active metabolite with similar biochemical and biological properties to those of the 1α,25(OH)2D3.

Indexed as

Cell DifferentiationCell ProliferationCells, CulturedCholecalciferolCrystallography, X-RayHL-60 CellsHumansProtein BindingProtein Structure, SecondaryProtein Structure, TertiaryReceptors, CalcitriolCholecalciferolReceptors, Calcitriol

Identifiers

PMID21483824
PMCPMC3069065
OpenAlexW1971983632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.